Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.
NCT04710732 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 9
Last updated 2025-01-07
Summary
The aim of this study is to evaluate the efficacy and safety of individual dose adjustment of low molecular weight heparin (LMWH) based on the results of the thrombodynamics test (TD) in patients at extremely high risk of postoperative venous thromboembolism (VTE).
This is a single-center, open-label, randomized clinical study with a blinded assessor for primary efficacy outcome.
Patients after elective or emergent major surgery having 10 or more Caprini scores at the baseline, who already received two subcutaneous injections of enoxaparin: 40 mg at 6-12 hours after the surgery ("key injection 1") and 40 mg at 12 hours after the previous injection ("key injection 2"), who had no VTE at the baseline, and who signed informed consent, are subjected to laboratory examination by the TD.
Blood samples are taken 12 hours after the "key injection 1" and 24 hours after the "key injection 2". If one of the relevant parameters of the TD (initial velocity of clot growth rate and clot size) exceeds the set threshold, the Caprini scores are recalculated adding 3 points for "other thrombophilic state" confirmed by the thrombodynamics. The patient may be included in the study if the new sum exceeds 13 points (initial 10 scores + additional 3 scores). Within 60 hours from the surgery, the included patients are randomly allocated to one of two groups: Experimental or Control. Patients in the Control group continue to receive the standard dose of enoxaparin 40 mg every 24 hours (once daily). In the Experimental group, the dose of enoxaparin is increased to 30 mg every 12 hours (twice daily).
Blood samples for TD are taken during the next two days at 24 hours after the administration of each daily dose of enoxaparin.
A whole leg duplex ultrasound scan (DUS) is performed in all patients during the screening period and at 7-10 days after the surgery or in case of any suspicion for deep vein thrombosis (DVT) or superficial vein thrombosis (SVT). Computed tomography pulmonary angiography (CTPA) is carried out in any clinical suspicion for pulmonary embolism (PE). An autopsy is performed in all dead patients.
The total follow-up period is 30 days. After discharge, patients are invited to the hospital for clinical examination with DUS or interviewed by phone to identify symptomatic VTE.
Conditions
- Venous Thromboembolism
Interventions
- DRUG
-
Standard Enoxaparin 40 mg once-daily before randomization
Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule: * 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1) * 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0) * 12 hours after the previous key injection 1 (key injection 2) on the POD 1 * 24 hours after the previous key injection 2 on the POD 2
- DRUG
-
Standard Enoxaparin 40 mg once-daily after randomization
Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge
- DRUG
-
Escalated Enoxaparin 30 mg twice-daily after randomization
Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge
- DEVICE
-
Anti-embolic elastic compression stockings
Applied before or just after the surgery and used around the clock until discharge
- DIAGNOSTIC_TEST
-
Thrombodynamic test (TD)
Blood sampling for TD: * 12 hours after key injection 1 (TD-12) on the POD 1 * 24 hours after key injection 2 (TD-24) on the POD 2 * 24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)
Sponsors & Collaborators
-
Pirogov Russian National Research Medical University
lead OTHER
Principal Investigators
-
Kirill Lobastov, PhD · Pirogov RNRMU
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-01
- Primary Completion
- 2023-12-31
- Completion
- 2024-01-31
Countries
- Russia
Study Locations
More Related Trials
-
Thromboprophylaxis in Critically Ill Patients
NCT00437697 ·Status: TERMINATED ·Phase: PHASE4
-
Below Knee DVT Study
NCT03805672 ·Status: TERMINATED ·Phase: PHASE4
-
Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin
NCT05819125 ·Status: TERMINATED
-
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
NCT00793234 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.
NCT04671160 ·Status: UNKNOWN
-
A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness
NCT05819112 ·Status: TERMINATED
-
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
NCT00152971 ·Status: COMPLETED ·Phase: PHASE3
-
Nadroparin for the Initial Treatment of Pulmonary Thromboembolism
NCT00796692 ·Status: COMPLETED ·Phase: PHASE4
-
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
NCT00408239 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
NCT02412982 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
NCT01662908 ·Status: COMPLETED ·Phase: PHASE2
-
Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
NCT02704052 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
NCT01828697 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Sodium Heparin for Prophylaxis of Venous Thromboembolism in Surgical Patients
NCT00934167 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities
NCT00628576 ·Status: COMPLETED ·Phase: PHASE3
-
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
NCT00077753 ·Status: COMPLETED ·Phase: PHASE4
-
A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients
NCT00451412 ·Status: COMPLETED ·Phase: PHASE3
-
Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study
NCT03988231 ·Status: WITHDRAWN ·Phase: PHASE4
-
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
NCT02334007 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
NCT00311753 ·Status: COMPLETED ·Phase: PHASE3
-
Continuous Heparin Infusion to Prevent Catheter-related Thrombosis
NCT04767113 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
NCT00843492 ·Status: COMPLETED ·Phase: PHASE3
-
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
NCT07140211 ·Status: RECRUITING ·Phase: PHASE3
-
inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
NCT06581965 ·Status: RECRUITING ·Phase: PHASE4
-
Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching
NCT03483181 ·Status: UNKNOWN